Literature DB >> 1424752

Epitopes and idiotypes in experimental autoimmune uveitis: a review.

H S Dua1, M Abrams, J A Barrett, D S Gregerson, J V Forrester, L A Donoso.   

Abstract

Retinal S-antigen (SAg) and interphotoreceptor retinol-binding protein (IRBP) induced experimental autoimmune uveitis (EAU) and experimental autoimmune pinealitis (EAP) are good models for studying the mechanisms involved in autoimmune diseases. Many immunogenetically active epitopes have been identified in these proteins but immunodominance of one or more epitopes in vivo, has not yet been established. In this paper we present and discuss some experiments that led to the discovery of a dominant "tolerogenic" epitope in SAg. We also demonstrate the presence of cross reactive epitopes in the two potent retinal antigens, SAg and IRBP and finally introduce early data on a unique anti S2.4.c5 idiotypic (Id) monoclonal antibody (MAb) which appears to be a site non associated antibody that binds not only to s2.4.c5 but also to SAg.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1424752     DOI: 10.3109/02713689208999512

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  3 in total

1.  Beta-arrestin and arrestin are recognized by autoantibodies in sera from multiple sclerosis patients.

Authors:  H Ohguro; S Chiba; Y Igarashi; H Matsumoto; T Akino; K Palczewski
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

2.  Interphotoreceptor retinoid-binding protein as biomarker in systemic autoimmunity with eye inflictions.

Authors:  F J Descamps; D Kangave; B Cauwe; E Martens; K Geboes; A Abu El-Asrar; G Opdenakker
Journal:  J Cell Mol Med       Date:  2008-02-04       Impact factor: 5.310

Review 3.  Are Anti-Retinal Autoantibodies a Cause or a Consequence of Retinal Degeneration in Autoimmune Retinopathies?

Authors:  Grazyna Adamus
Journal:  Front Immunol       Date:  2018-04-16       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.